New combo attack shrinks untreatable liver tumors
NCT ID NCT07230314
First seen Nov 17, 2025 · Last updated May 12, 2026 · Updated 14 times
Summary
This study tests a powerful mix of treatments for people with liver cancer that cannot be surgically removed. It combines two types of local therapy (TACE and SBRT) with an immunotherapy drug and a targeted pill (donafenib). The goal is to see if this combination can shrink tumors and control the disease. 34 adults aged 18-75 who have not had prior treatment for this stage of cancer will participate.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.